Goldman Sachs’s MoonLake Immunotherapeutics MLTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.1M Buy
1,130,233
+859,568
+318% +$14.2M ﹤0.01% 2386
2025
Q4
$3.57M Sell
270,665
-92,206
-25% -$1.09M ﹤0.01% 4069
2025
Q3
$2.6M Sell
362,871
-912,698
-72% -$47.6M ﹤0.01% 4254
2025
Q2
$60.2M Sell
1,275,569
-17,039
-1% -$694K 0.01% 1204
2025
Q1
$50.5M Sell
1,292,608
-382,056
-23% -$16.5M 0.01% 1219
2024
Q4
$90.7M Buy
1,674,664
+178,833
+12% +$9.13M 0.01% 861
2024
Q3
$75.4M Buy
1,495,831
+244,084
+19% +$11.4M 0.01% 944
2024
Q2
$55M Buy
1,251,747
+1,093,587
+691% +$46.3M 0.01% 1100
2024
Q1
$7.94M Buy
158,160
+7,026
+5% +$381K ﹤0.01% 2693
2023
Q4
$9.13M Buy
151,134
+54,447
+56% +$2.81M ﹤0.01% 2617
2023
Q3
$5.51M Buy
96,687
+7,186
+8% +$397K ﹤0.01% 2898
2023
Q2
$4.56M Buy
+89,501
New +$2.41M ﹤0.01% 3180
2023
Q1
Sell
-10,110
Closed -$106K 6120
2022
Q4
$106K Sell
10,110
-100
-1% -$889 ﹤0.01% 5469
2022
Q3
$79K Sell
10,210
-1,575
-13% -$11.1K ﹤0.01% 5734
2022
Q2
$62K Buy
+11,785
New +$74.1K ﹤0.01% 5981

Other funds holding MLTX